Funded by LUNGevity Foundation in collaboration with The CHEST Foundation, the philanthropic arm of the American College of Chest Physicians
William Jeffrey Petty, MD
Dartmouth-Hitchcock Medical Center
Lebanon
Bexarotene is a synthetic form of retinoid acid (Vitamin A) that has the potential for use in lung cancer chemoprevention. Dr. Petty is conducting a clinical trial with a treatment combination of bexarotene and erlotinib (Tarceva) in EGFR-positive patients who have metastatic non-small cell lung cancer (NSCLC). He is also evaluating biomarkers that will predict response to the combination regimen.